Fingolimod

5 trials 2 recruiting LOncology

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

5 Sponsors

18 Countries

Phase III

Phase II/III

Phase II

Phase III: 3 Phase II/III: 1 Phase II: 1

Oversight events:

1 unexpected event across 1 trial

View oversight register →

Indications tested

Relapsing-remitting multiple sclerosis 2 Multiple sclerosis 1 Relapsing multiple sclerosis 1 Progressive multiple sclerosis 1 Primary progressive multiple sclerosis 1 Secondary progressive multiple sclerosis 1

Sponsors using this IMP

Antwerp University Hospital 1 Bristol-Myers Squibb Services Unlimited Company 1 F. Hoffmann-La Roche AG 1 Novartis Pharma AG 1 Tg Therapeutics Inc. 1

All trials

5 total

Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS) Recruiting

2025-522257-19-00 Phase II/III 2 countries Tg Therapeutics Inc.
A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents wi… Recruiting

2022-501332-42-00 Phase III 5 countries Bristol-Myers Squibb Services Unlimited Company
Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended

2023-503190-38-00 Phase II 1 country Antwerp University Hospital
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu… Ended

2023-506516-40-00 Phase III 17 countries F. Hoffmann-La Roche AG
A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety and efficacy of fingolimod admi… Ended

2023-507556-68-00 Phase III 5 countries Novartis Pharma AG

Showing 1–5 of 5 trials

← All drugs A–Z